FAM171A2

Across TCGA pan-cancer cohorts, FAM171A2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM171A2 data layer compared with 29 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FAM171A2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FAM171A2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

HNSC, LSCC, and GBM are the cancer types where FAM171A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.839	0.410	.006	15	view →
LSCC	DFS	Median	All	0.322	1.000	.002	6	view →
GBM	DFS	Tertile	All	0.916	0.700	.002	5	view →
LUAD	OS	Median	III,IV	0.194	0.879	.010	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FAM171A2–HNSC (DFS)

Open the HNSC breakdown →